The Alice Lee Centre for Nursing Studies at NUS in Singapore introduces the Supportive Parenting Application (SPA), a groundbreaking tool offering vital support for those navigating the complexities of early parenthood. Developed in response to the unique challenges faced by parents, SPA provides localized guidance through a variety of mediums, such as videos, podcasts, and articles. A team of experts, including obstetricians, psychiatrists, nurses, and midwives from reputable healthcare institutions in Singapore, curates this valuable content.

Key Features

SPA is more than just an information hub. It provides an interactive experience for parents, with features like:

• Tailored Guidance: The app offers insights into parental self-care, baby care tutorials, and effective coping strategies for the psychological and emotional challenges post-birth.
• Community Interaction: A discussion forum allows parents to post queries and engage with each other. The app also features a chat function, connecting parents with trained peer volunteers who provide invaluable emotional support.

Research Findings

Associate Professor Shefaly Shorey and her team at NUS Nursing conducted a comprehensive study, focusing on the effectiveness of SPA during the difficult times of the COVID-19 pandemic. The study observed significant positive outcomes for both parents and infants, including:

• Improved Parental Outcomes: SPA users demonstrated enhanced perceived social support, higher help-seeking scores during the post-childbirth period, and a gradual reduction in depressive symptoms among mothers over time.
• Positive Infant Development: Infants of SPA users exhibited better cognitive, motor, communication, and social skills. This resulted in a notable reduction in the risk of developmental delays compared to infants whose parents did not use the app.

Future Plans

The research team, fueled by the success of the initial study, plans to further enhance SPA. They aim to expand their evaluation to include parents facing psychosocial disadvantages and vulnerable backgrounds, such as those with low socio-economic status or children with special needs. The ultimate goal is to make the SPA and its valuable content accessible to a broader audience of local parents in the coming years.

Assoc. Prof. Shefaly Shorey emphasized, “Our study proved that the mobile health intervention was a good source of evidence-based yet localized information and reliable support to help parents care for newborns and their own emotional and overall well-being.” The SPA app represents a significant leap in leveraging technology to provide holistic perinatal support for parents.

Available nationwide without a prescription, EndeavorOTC users can now access their personalized Focus Score and track progress towards clinically-meaningful improvements in attention.

BOSTON–(BUSINESS WIRE)–Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that EndeavorOTC, the mobile video game treatment clinically proven to improve attention and focus in adults with ADHD, is now available on Google Play for popular Android devices, including most Samsung Galaxy and Google Pixel models. Out of the estimated 11 million adults living with ADHD in the United States, approximately 40% are Android users so we believe this release represents a crucial step in offering an accessible non-drug treatment option to adults with ADHD, particularly amid the continued stimulant medication shortage and ongoing mental health crisis.

EndeavorOTC is built on the same technology as Akili’s EndeavorRx^®, the world’s first and only FDA-authorized video game treatment, for children 8-12 years old with ADHD. In a recent clinical trial, EndeavorOTC significantly improved focus, attention, and overall quality of life in adults struggling with ADHD symptoms. On average, participants’ ability to focus improved by 85%*; over one-third of participants no longer exhibited an attention deficit following treatment*, and 73% of participants reported quality of life improvements**.

“Video games are an established part of life for the majority of American adults,” said Jon David, chief product officer of Akili. “By delivering an ADHD treatment via video game, we believe we’re tapping into established habits and making a clinically-proven treatment more accessible and approachable than ever before. With the launch of EndeavorOTC on Android, we’re continuing to break down barriers to care, making our treatment available to millions of adults who may benefit.”

The release of EndeavorOTC comes at a time when the ADHD community faces continued challenges accessing care. Fueled by manufacturing issues and record-high prescription rates, the stimulant shortage continues and now affects multiple ADHD drugs. Last month, the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) issued a joint statement on the ongoing nationwide shortage of stimulants for the treatment of conditions such as ADHD, noting the FDA’s support of non-drug treatment options including Akili’s EndeavorRx product.

The Android release follows EndeavorOTC’s release on the Apple iOS App Store^® in June 2023. EndeavorOTC now features Akili’s recently released Focus Score, a new metric for users. Focus Score provides a measurement of how quickly and accurately patients can complete a task despite distractions during gameplay, assisting with setting benchmarks and quantifying progress. A patient’s personalized baseline Focus Score is calculated during treatment onboarding, along with a target Focus Score that serves as a treatment goal. In Akili’s recent adult ADHD clinical trial, Focus Score improvements were directly related to improvement in ADHD-related symptoms and overall quality of life—things like being able to complete tasks or keep track of important items like your wallet and keys.

For more information, visit EndeavorOTC.com. EndeavorOTC is available for download without a prescription for adults 18 years of age and older on Android’s Google Play or Apple’s App Store.

*As measured by an improvement ≥ 1.4 on the TOVA® ACS. Changes in the Focus Score are statistically significantly related to changes in TOVA and other outcomes. Treatment results may vary. Internal data on file.

**As measured by the validated Adult ADHD Quality of Life Scale (AAQoL). Internal data on file.

About EndeavorOTC and EndeavorRx

Akili’s suite of cognitive treatment products for ADHD includes EndeavorOTC and EndeavorRx.

EndeavorOTC is a digital therapeutic indicated to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined-type ADHD. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is available under the U.S. Food and Drug Administration’s current Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. EndeavorOTC has not been cleared or authorized by the U.S. Food and Drug Administration for any indications. It is recommended that patients speak to their health care provider before starting EndeavorOTC treatment. No serious adverse events have been reported in any of our clinical studies. To learn more, visit EndeavorOTC.com.

EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication. The most common side effect observed in children in EndeavorRx’s clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child’s health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

These forward-looking statements include, without limitation, statements in this press release related to: the ability of adults to access and use EndeavorOTC; the ability of EndeavorOTC to improve attention function, ADHD symptoms and quality of life in adults with ADHD; and the growing need for ADHD treatment and non-drug options. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the risk that prior results, such as signals of efficacy or safety observed from clinical trials will not continue or be repeated in EndeavorOTC or our ongoing or planned clinical trials for this or any other product, or will be insufficient to support regulatory submissions or to obtain, support or maintain marketing approval in the United States or other jurisdictions, or that long-term adverse safety findings may be discovered; the risk that our products will not be further developed or commercialized successfully; the timing and results expected from our and our partners’ clinical trials and our reliance on third parties for certain aspects of our business; our ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in our current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing the company’s views as of any subsequent date. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contacts

Investors:
Santosh Shanbhag
Chief Financial Officer
InvestorRelations@akiliinteractive.com

Media:
Caty Reid
VP, Marketing & Communications
PR@akiliinteractive.com

NEW YORK–(BUSINESS WIRE)–Noom for Work, the commercial leader in behavior change, announced today that it would deliver two new preventive health solutions to commercial members of CareFirst BlueCross BlueShield’s (CareFirst): Noom Weight and Noom’s Diabetes Prevention Program. Beginning April 3, 2023, both programs will be accessed via CareFirst WellBeing℠ as a benefit to all commercial members, opening up always-on access to Noom’s psychology-based app for the full member population. Users will take a brief assessment in the app to determine the program that best fits their profile.

For some users, Noom Weight, the organization’s flagship program, will be the best fit. Powered by psychology, Noom Weight uses evidence-based techniques to empower behavior change. It’s a personalized, mind-first approach that combines technology and human coaching to create healthier habits that lead to long-lasting results. Features of Noom Weight include curriculum that teaches users the why behind their habits and how to change them; modular daily lessons, tailored to each person’s goals; education tracking, food logging, and ability to connect to other devices (scales, wearables) for immediate feedback and positive reinforcement; and one-on-one coaching and peer support groups to help improve outcomes via encouragement, accountability, and goal setting.

“Partnering with Noom to integrate its solutions into the CareFirst WellBeing application was a natural move for the redesigned platform,” said Mack McGee, Vice President and Chief Marketing Officer of CareFirst. “With specific focus on preventive care to yield better health outcomes, CareFirst WellBeing is prioritizing innovative programs that fit into daily life and meet people where they are in their healthcare journey. This partnership with Noom will empower the people we serve to take charge of their health through healthier habits and weight management to mitigate chronic conditions, and we’re excited to see the benefits it brings to our members.”

For other individuals at risk for type 2 diabetes, they will receive Noom’s Diabetes Prevention Program (DPP) – the first CDC-recognized digital behavior change program tailored to support those who have early indicators of the disease. Eligible members will be screened for enrollment based on meeting standard criteria for prediabetes and access a digital experience similar to Noom Weight, but tailored to a prediabetes audience. DPP carries the same core features of Noom’s Weight program, but also includes daily lessons tailored to each user’s goals and aligned with CDC requirements, including a weekly exercise minutes goal tracker and one-on-one coaching with trained DPP lifestyle coaches, with a heavier emphasis on peer support and group interaction.

According to the CDC, more than 72% of the Adult US population is overweight, and more than half of that population is obese, with trends predicted to increase every year – and 47% of chronic conditions can be attributed to being overweight.

“So much of the impact on weight in the US is based on the lifestyle choices we make and we know how hard it is to retrain your brain to develop healthier habits in a way that is easy, accessible and personalized. We’re extremely excited to partner with an innovative organization like CareFirst who is prioritizing the health of its members with programs like Noom, which can be accessed by its full population to help develop healthier habits that last, ultimately reduce the risk of chronic conditions and the prevalence of type 2 diabetes,” said Matt Mouradian, General Manager of Healthcare at Noom.

About Noom

Noom is a psychology-based digital health platform powered by data, technology, and human coaches that helps millions of people meet their personal health and wellness goals from weight management to diabetes prevention to stress reduction. The company has been awarded multiple grants from the National Institutes of Health and was the first mobile application to be recognized by the Centers for Disease Control and Prevention as a certified diabetes prevention program. Headquartered in New York City, Noom has been named one of Inc.’s Best Places to Work, Quartz’s Best Workplaces for Remote Workers, and Fortune’s Best Workplaces in Technology.

Contacts

Noom Communications
comms@noom.com